New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
09:11 EDTPXD, MDCI, NSPH, MON, IMS, SQBG, GLNG, BMY, BKS, CVRR, OMI, AERI, GISOn The Fly: Pre-market Movers
HIGHER: Barnes & Noble (BKS), up 7.7% after board authorizes management to separate Retail, Nook Media units... Monsanto (MON), up 5% after reporting better than expected Q3 results, raising its full year EPS outlook to the upper end of its previous guidance range and announcing a new $10B share repurchase authorization... IMS Health (IMS), up 7.7% after acquiring certain Cegedim businesses for $520M... Nanosphere (NSPH), up 16.2% after receiving 510(k) clearance for bacterial portion of Verigene EP test... Aerie Pharmaceuticals (AERI), up 37% after its trial of Roclatan achieved its primary efficacy endpoint... Medical Action (MDCI), up 94% after Owens & Minor (OMI) acquires the company for $13.80 per share in cash... Sequential Brands (SQBG), up 15% after acquiring Galaxy Brand for $100M cash, 13.75M shares... Pioneer Natural (PXD), up 2.3% after media reports that the company got U.S. permission to ship a type of light oil known as condensate... Bristol-Myers Squibb (BMY), up 2% after a Phase 3 study of nivolumab was halted early due to superior data. LOWER: General Mills (GIS), down 3.7% after Q4 earnings fall below analyst's consensus... Lindsay Corp. (LNN), down 5% after earnings miss, saying Iraq contract now more difficult to complete... Golar LNG (GLNG), down 2% after 11M share offering priced at $54 per share... CVR Refining (CVRR), down 7% after 6M share secondary offering of common units price at $26.07.
News For BKS;MON;GIS;BMY;NSPH;AERI;GLNG;MDCI;OMI;SQBG;PXD;CVRR;IMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 24, 2014
14:35 EDTBKSBarnes & Noble volatility increases into Q2 and outlook
Subscribe for More Information
13:47 EDTGLNGGolar LNG volatility elevated into Q3 and outlook
Subscribe for More Information
09:00 EDTBMYBristol-Myers, Five Prime announce clinical collaboration for Opdivo, FPA008
Subscribe for More Information
06:29 EDTBKSBarnes & Noble moves into gifts to reverse declines in store traffic, WSJ says
Subscribe for More Information
November 20, 2014
07:19 EDTSQBGPerry Ellis approached by 'at least' two buyers, including Iconix, NY Post says
Subscribe for More Information
November 19, 2014
07:52 EDTBMYInforma Business Information to hold a conference
Subscribe for More Information
06:48 EDTGISGeneral Mills to remove '100% Natural' from Nature Valley products, WSJ says
Subscribe for More Information
06:07 EDTBMYBristol-Myers' Opdivo for melanoma shows positive Phase 3 results
Subscribe for More Information
November 18, 2014
09:09 EDTAERIAerie Pharmaceuticals management to meet with Needham
Subscribe for More Information
07:37 EDTIMSStifel to hold a conference
Subscribe for More Information
06:30 EDTCVRRCVR Refining coverage resumed with a Neutral at Goldman
Subscribe for More Information
November 17, 2014
11:06 EDTBMYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:13 EDTBMYPortola, Bristol-Myers, Pfizer announce results from Phase 3 ANNEXA-A studies
Subscribe for More Information
08:10 EDTBMYBristol-Myers presents results from Phase IIIb AVERT trial at ACR
Bristol-Myers Squibb Company announced results of several new sub-analyses of the Phase IIIb AVERT trial that investigated the use of Orencia plus methotrexate in biologic and MTX-na´ve citrullinated protein-positive early moderate to severe rheumatoid arthritis patients. These data were presented this week at the American College of Rheumatology 2014 annual meeting. Orencia is currently indicated in adults for moderate to severe RA. Orencia should not be administered with tumor necrosis factor antagonists and should not be used with other biologic RA drugs. One of the analyses looked at anti-CCP antibodies, which are a marker of RA and may contribute to disease progression. The analysis assessed the development of anti-CCP antibodies in patients with early rapidly progressing RA by measuring isotypes and the number of epitopes recognized after treatment with Orencia plus MTX, Orencia alone, or MTX alone. Results demonstrated Orencia plus MTX numerically reduced the concentrations of all CCP isotypes and the average number of epitopes recognized over one year of treatment more than Orencia alone or MTX alone. Over 12 months of treatment, 6.7 percent, 12.1 percent, and 7.8 percent of patients on Orencia plus MTX, Orencia alone, and MTX alone, respectively, experienced a serious adverse event and 1.7 percent, 4.3 percent and 2.6 percent led to discontinuation. Serious infections were observed in 0.8 percent of patients in the combination arm and 3.4 percent in the Orencia monotherapy arm. None of the patients in the MTX alone arm experienced a serious infection. Malignancies were reported in 0.8 percent, 1.7 percent, and 0 percent of patients in the Orencia + MTX, Orencia, and MTX arms, respectively. Additionally at ACR, investigators presented 12-month efficacy data from AVERT, including new results assessing the effect of Orencia on more clinically stringent remission criteria than DAS-defined remission, as well as new MRI data. Significantly more patients on Orencia plus MTX achieved the stringent clinical endpoint of Boolean-defined remission at 12 months.
November 16, 2014
13:07 EDTBMYBristol-Myers announces results from CheckMate -066 study
Subscribe for More Information
November 14, 2014
14:53 EDTBMYCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
13:23 EDTSQBGPerry Ellis recently approached about takeover by Sequential Brands, WSJ says
Perry Ellis (PERY) was recently approached about a takeover by Sequential Brands (SQBG), according to The Wall Street Journal, citing people familiar with the matter. The Fly notes that TheStreet reported this morning that Perry Ellis has been interviewing banks, including Peter J. Solomon and BofA Merrill Lynch, to advise on its next steps. On July 17, Legion Partners reported a 5.9% stake in Perry Ellis and called on the company's board to "undertake a thorough review of all strategic alternatives." Perry Ellis shares are up 1% to $23.17 in afternoon trading. Reference Link
12:40 EDTSQBGPerry Ellis recently approached about takeover by Sequential Brands, WSJ says
Subscribe for More Information
07:14 EDTBMYAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
06:05 EDTBMYBristol-Myers to construct biologics manufacturing facility in Ireland
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use